Plain-English translation of NCT04844528 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a form of vitamin B3, to see if it can help prevent new skin cancers from developing in people who have both chronic lymphocytic leukemia (a blood cancer) and a history of non-melanoma skin cancer. About half of participants will take the medication for one year while the other half takes a placebo (fake pill), and then everyone will take the medication for a second year. The goal is to see whether this medication reduces the number of new skin cancers that develop.
People with chronic lymphocytic leukemia are at higher risk for developing multiple skin cancers over time. Researchers want to find a safe, simple way to help prevent these cancers from coming back, and this medication is a promising option that has shown some benefit in other groups of patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to take either the medication or a placebo pill twice daily for one year. You'll have a skin check by a dermatologist at the one-year mark to count any new skin cancers. After that, everyone will know which group they were in and will take the actual medication for a second year, with another skin check at the end. Throughout the trial, you may have blood tests and skin biopsies to help researchers understand how the treatment works.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States